FOLH1 and neoplasm: Both of the FDA-approved and commercially available PSMA ligands may show increased uptake of radiotracer in a wide range of other solid tumors, both benign and malignant, including high grade glioma, breast cancer, meningioma, hepatocellular carcinoma, renal cell carcinoma, lung cancer, GIST tumor, urothelial carcinoma, hepatic hemangiomas, testicular/embryonal and others [118].